Detecting Toxic Myopathies as Medication Side Effect - 05/10/18
Doi : 10.1016/j.pmr.2018.06.002
Elba Gerena-Maldonado, MD ⁎ 
Department of Physical Medicine and Rehabilitation, Providence St. Joseph Health, Providence Medical Group, 500 West Broadway, 3rd Floor, Missoula, MT 59802, USA
∗Corresponding author. Physical Medicine and Rehabilitation Clinic, 500 West Broadway, 3rd Floor, Missoula, MT 59802.Physical Medicine and Rehabilitation Clinic500 West Broadway3rd FloorMissoulaMT59802
Résumé |
The goal of this article is to provide physiatrists, neurologists, and neuromuscular medicine physicians a framework that can be easily used in the process of evaluating, identifying, and treating patients with toxic myopathies. This review attempts to classify these rare but potentially deadly conditions in clinical patterns and distinguishes the cellular mechanisms in which the offending agents tend to impact the structure and function of myocytes.
Le texte complet de cet article est disponible en PDF.Keywords : Toxic myopathy, Rhabdomyolysis, Muscle weakness, Electrodiagnostic studies, Muscle biopsy
Plan
| Disclosure Statement: Nothing to disclose. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 29 - N° 4
P. 659-667 - novembre 2018 Retour au numéro
Article précédent
- Value-Added Electrodiagnostics : Targeting Interventions for Fall Risk Reduction
- Sandra L. Hearn, James K. Richardson
- Electrodiagnostic Testing for the Diagnosis and Management of Amyotrophic Lateral Sclerosis
- Ileana M. Howard, Nassim Rad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?